Masood A - Search Results

1

Association of medical uninsurance with sociodemographic attributes in US cancer population: A cross-sectional study of NHANES data 2013 to 2018.

Wahab A, Abdelazeem B, Masood A, Khakwani M, Kumar Jakka B, Koduru U, Ehsan H. Wahab A, et al. Among authors: masood a. Medicine (Baltimore). 2022 Sep 23;101(38):e30539. doi: 10.1097/MD.0000000000030539. Medicine (Baltimore). 2022. PMID: 36197243 Free PMC article.

2

Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma.

Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, Khan A. Wahab A, et al. Among authors: masood a. Front Oncol. 2021 May 11;11:678634. doi: 10.3389/fonc.2021.678634. eCollection 2021. Front Oncol. 2021. PMID: 34046363 Free PMC article. Review.

3

Efficacy and safety of allogeneic hematopoietic stem cell transplant in adults with hemophagocytic lymphohistiocytosis: a systematic review of literature.

Masood A, Wahab A, Iqbal Q, Davis J, Ehsan H, Hashmi H. Masood A, et al. Bone Marrow Transplant. 2022 Jun;57(6):866-873. doi: 10.1038/s41409-022-01668-9. Epub 2022 Apr 11. Bone Marrow Transplant. 2022. PMID: 35411107 Review.

4

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.

Masood A, Wahab A, Clifford T, Weaver EJ, Ehsan H, El Ayass W. Masood A, et al. Clin Case Rep. 2021 Dec 5;9(12):e05184. doi: 10.1002/ccr3.5184. eCollection 2021 Dec. Clin Case Rep. 2021. PMID: 34917381 Free PMC article.

5

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

Neupane K, Wahab A, Masood A, Faraz T, Bahram S, Ehsan H, Hannan A, Anwer F. Neupane K, et al. Among authors: masood a. J Blood Med. 2021 Jul 1;12:529-550. doi: 10.2147/JBM.S317966. eCollection 2021. J Blood Med. 2021. PMID: 34234609 Free PMC article. Review.

6

Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma.

Ehsan H, Wahab A, Shah Z, Sana MK, Masood A, Rafae A, Hashmi H. Ehsan H, et al. Among authors: masood a. J Hematol. 2021 Jun;10(3):89-97. doi: 10.14740/jh844. Epub 2021 Jun 16. J Hematol. 2021. PMID: 34267845 Free PMC article. Review.

7

Treatment of Light Chain Deposition Disease: A Systematic Review.

Masood A, Ehsan H, Iqbal Q, Salman A, Hashmi H. Masood A, et al. J Hematol. 2022 Aug;11(4):123-130. doi: 10.14740/jh1038. Epub 2022 Aug 30. J Hematol. 2022. PMID: 36118549 Free PMC article. Review.

8

Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.

Ehsan H, Rafae A, Masood A, Wahab A, Sana MK, Ansar I, Neupane K, Umar A, Ehsan A, Hashmi H. Ehsan H, et al. Among authors: masood a. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e285-e292. doi: 10.1016/j.clml.2021.10.014. Epub 2021 Nov 1. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34879994 Review.

9

Durable remission of acute myeloid leukemia in an elderly patient following a limited course of azacitidine and venetoclax.

Ehsan H, Iqbal Q, Masood A, Grunwald MR. Ehsan H, et al. Among authors: masood a. Leuk Res Rep. 2022 Aug 17;18:100345. doi: 10.1016/j.lrr.2022.100345. eCollection 2022. Leuk Res Rep. 2022. PMID: 36051639 Free PMC article.

10

Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.

Masood A, Iqbal Q, Ehsan H, Davis JA, Hansen DK, Hashmi H. Masood A, et al. Ann Hematol. 2022 Dec;101(12):2601-2610. doi: 10.1007/s00277-022-04999-1. Epub 2022 Oct 10. Ann Hematol. 2022. PMID: 36214853 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

515 results

Search Page

Filters